Abstract: Calprotectin inhibitors and derivatives thereof, and methods of using them for inhibiting or reducing metastatis and treating cancer are provided. The pharmaceutical formulations prepared from the compounds can be used in the treatment of cancer either as a single agent or in combination with at least one other cancer therapeutic, chemotherapeutic or anti-cancer agent.

Abstract: The present invention relates to a compound based on cyanine scaffold for diagnosing sepsis by selectively detecting glutathione. The compound based on cyanine scaffold according to the present invention has the advantages of maintaining its structure in intracellular environment and of reacting selectively to glutathione only among many amino acids containing thiol group (R—SH) such as cysteine, homocysteine, and glutathione, to produce changes in absorption or fluorescence spectrum, making the compound useful for the detection of in vivo glutathione in biosamples and also for the diagnosis of sepsis characteristically displaying the changes of glutathione concentration.

Abstract: There are provided compounds comprising optionally substituted (FORMULA I) fused with one or two optionally substituted (FORMULA II), wherein A and E each independently represent —CH2—, —NH—, —O—, —S—, or —C(?O)— and B represents a bond, —CH2—, —NH—, —O—, —S—, or —C(?O)—, said compound having directly or indirectly attached thereto at least one acyl and/or oxime ester group. Such compounds are useful inter alias as photoinitiators.

Abstract: An organic electroluminescent element including a luminescent compound represented by the following formula (in which R1 to R14 each independently represent a hydrogen atom, a deuterium atom, an alkyl group, an aryl group, a heteroaryl group, a fluorine atom, a cyano group, an amino group, an alkoxy group, an aryloxy group, a thio group, or a silyl group, and 8 to 13 groups out of R1 to R14 each represent a hydrogen atom or a deuterium atom.) in a light emitting layer has high durability and excellent chromaticity.

Abstract: The present invention relates to the use of a compound of formula 1, a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, for the treatment of an inflammatory disorder. The invention further relates to a pharmaceutical composition comprising a compound of formula 1 and at least one pharmaceutically acceptable carrier, for use in the treatment of an inflammatory disorder. The invention also relates to a method for the treatment of an inflammatory disorder by administering a therapeutically effective amount of the compound of formula 1 to a subject in need thereof.

Abstract: A heterocyclic compound wherein three five-membered rings are fused to one benzene ring and a saturated or unsaturated ring is fused to each five-membered ring. An organic electroluminescence device includes one or more organic thin film layers between an anode and a cathode. The one or more organic thin film layers include a light emitting layer. At least one layer of the one or more organic thin film layers includes the heterocyclic compound.

Abstract: The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof.

Abstract: This application relates, in part, to an organic electroluminescent element including a substrate, a pair of electrodes including an anode and a cathode, disposed on the substrate, and at least one organic layer including a light emitting layer, disposed between the electrodes, in which at least one layer of the organic layer(s) contains a compound represented by the following formula (1). The organic electroluminescent element has low driving voltage and excellent durability. wherein X1 to X11 represent CR0 or N, and R0 represents a hydrogen atom or a substituent. Adjacent two of X1 to X11 each independently represent at least CR0, R0s of the adjacent two CR0s are bonded to each other to form a ring, and only one R0 of the adjacent two CR0s represents an aryl group or a heteroaryl group.

Abstract: An organic compound has a dibenzo[8,9:10,11]tetrapheno[5,6-b]carbazole skeleton as a basic skeleton. An organic light-emitting device includes an anode, a cathode, and an organic compound layer including the organic compound. A display apparatus includes a plurality of pixels, and each of the pixels includes the organic light-emitting device and a transistor. An image display system includes an input section and a display section including the display apparatus. A lighting apparatus includes the organic light-emitting device and an inverter circuit. An electrophotographic image-forming apparatus includes a light source including a plurality of the organic light-emitting devices and a photosensitive member.

Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein R1 to R12 are defined as in the specification.

Abstract: The present invention discloses a novel ditriphenylene derivative is represented by the following formula (I), the organic EL device employing the ditriphenylene derivative as host material or dopant material of emitting layer can lower driving voltage, prolong half-life time and increase the efficiency. Wherein m, n represent an integer of 0 to 10. X is a divalent bridge selected from the atom or group consisting from O, S, C(R3)(R4), NR5, Si(R6)(R7). Ar1, Ar2, R1 to R7 are substituents and the same definition as described in the present invention.

Abstract: There are provided compounds comprising optionally substituted (FORMULA I) fused with one or two optionally substituted (FORMULA II), wherein A and E each independently represent —CH2—, —NH—, —O—, —S—, or —C(?O)— and B represents a bond, —CH2—, —NH—, —O—, —S—, or —C(?O)—, said compound having directly or indirectly attached thereto at least one acyl and/or oxime ester group. Such compounds are useful inter alias as photoinitiators.

Abstract: The present invention provides a novel compound that is capable of largely improving a life span, efficiency, electrochemical stability and thermal stability of an organic light emitting device, and an organic light emitting device in which the compound is included in an organic compound layer.

Abstract: The present invention discloses a novel organic compound is represented by the following formula(I), the organic EL device employing the organic compound as host material or dopant material of emitting layer and/or as electron transporting material can lower driving voltage, prolong half-lifetime and increase the efficiency. wherein m represent an integer of 0 to 10, n represent an integer of 0 to 2. X is a divalent bridge selected from the atom or group consisting from O, S, C(R5)2, N(R5), Si(R5)2. Ar, R1 to R4 are substituents and the same definition as described in the present invention.

Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Abstract: The present invention relates to crosslinkable compounds, to the crosslinked compounds obtained from these compounds, and to processes for the preparation thereof. The invention is furthermore directed to the use of these compounds in electronic devices and to the corresponding electronic devices themselves.

Abstract: Embodiments described herein relate to compositions including iptycene-based structures and extended iptycene structures. In some embodiments, the compositions may be useful in organic light-emitting diodes (OLEDs), organic photovoltaics, and other devices.

Abstract: The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.

Abstract: A heterocyclic compound represented by Formula 1 below, and an organic light-emitting device including the heterocyclic compound:

Abstract: The present invention provides a novel compound that is capable of largely improving a life span, efficiency, electrochemical stability and thermal stability of an organic light emitting device, and an organic light emitting device in which the compound is included in an organic compound layer.

Abstract: Methods for forming maleimide functionalized polymers are provided. In one such embodiment, a maleimide functionalized polymer is prepared in a method that includes a step of carrying out a reverse Diels-Alder reaction. Intermediates useful in the methods, as well as methods for preparing the intermediates, are also provided. Also provided are polymeric reagents, methods of using polymeric reagents, compounds and conjugates.

Abstract: The present invention relates to a compound of a formula (I) or (II), to the use of this compound in an electronic device, and to an electronic device comprising one or more compounds of the formula (I) or (II). The invention furthermore relates to the preparation of the compound of the formula (I) or (II) and to a formulation comprising one or more compounds of the formula (I) or (II).

Abstract: A condensation compound is represented by Formula 1, 2, or 3 where R1 to R24 and A to F are further defined in the detailed description.

Abstract: The present invention relates to an electronic device comprising one or more compounds of a formula (I) or (II). Furthermore, the invention encompasses the use of a compound of the formula (I) or (II) in an electronic device, and the provision of certain compounds of the formula (I) or (II).

Abstract: A substituted indolocarbazole comprising at least one optionally substituted thienyl.

Abstract: This invention relates to a novel process for preparing compounds comprising moieties of formula (I) and polymers comprising monomers of formula (II) or (III) as defined herein. The present invention also provides novel compounds of formula (I) and novel polymers comprising monomers of formula (II) or (III) as defined herein, as well as to the use of such compounds and polymers in organic semiconductor applications.

Abstract: The invention relates to a photovoltaic coating containing a mixture of organic N-type (acceptor) and P-type (donor) semiconductor compounds, which makes it possible, when selecting the donor/acceptor pair, to modulate the semiconductor properties of the photovoltaic coating so as to enable the use thereof within a photovoltaic device, wherein one of the organic semiconductors includes a quinone core.

Abstract: The present invention provides a free radical polymerizable liquid crystal alignment agent having superior coating ability, a manufacturing method, which comprises the process of coating the liquid crystal alignment agent onto a substrate, and processing the liquid crystal alignment agent with dehydration/ring-closure reaction and free radical polymerization, enables obtaining a liquid crystal alignment film with superior reliability, superior voltage holding ratio and easy control of pretilt angle, and enables the manufacture of a liquid crystal display element provided with a liquid crystal alignment film. The free radical polymerizable liquid crystal alignment agent comprises a molecular compound containing at least 2 polymerizable maleamic acid groups and an organic solvent.

Abstract: Certain multi-cyclic compounds and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.

Abstract: A compound for absorbing sunlight and converting the sunlight into electrical energy, which is formed by coupling a fullerene with at least one or more triarylamine derivatives. The fullerene is selected from among those having carbon numbers C60, C70, C78, C82 and C84, and the triarylamine derivatives are coupled with at least one or more aliphatic or aromatic hydrocarbons and are also coupled with a dopant. A method of manufacturing the compound includes steps of synthesizing a fullerene derivative, synthesizing fullerene-triarylamine, wherein a fullerene-triarylamine adduct is prepared by coupling the fullerene derivative with a triarylamine derivative, preparing an adduct solution by dissolving the fullerene-triarylamine adduct in an organic solvent, and conducting a doping reaction by adding an acid dropwise slowly to the adduct solution.

Abstract: A heterocyclic compound of formula 1 and an organic light-emitting device including an organic layer containing the heterocyclic compound. The heterocyclic compound of Formula 1 may be suitable as a material for an emission layer, an electron transport layer or an electron injection layer of an organic light-emitting device. Due to the inclusion of the heterocylic group in its molecular structure, the heterocyclic compound of Formula 1 may have a high glass transition temperature (Tg) or a high melting point, and may prevent crystallization. An organic light-emitting device manufactured using the heterocyclic compound of Formula 1, which has a symmetrical structure in which a chrysene group and an indole group are fused, has excellent durability when stored or operated.

Abstract: A heterocyclic compound represented by a general Formula 1 and an organic light-emitting device including the heterocyclic compound. In some embodiments the heterocyclic compound of Formula 1 may be used as a light-emitting material, a hole transporting material, or an electron transporting material. The heterocyclic compound of Formula 1 having a heterocyclic group in the molecules thereof has a high glass transition temperature (Tg) or a high melting point due to the inclusion of the heterocyclic group. Thus, the heterocyclic compound has high heat resistance against Joule's heat generated in an organic layer, between organic layers, or between an organic layer and a metal electrode when light emission occurs, and has high durability in high-temperature environments. An organic light-emitting device manufactured using the heterocyclic compound of Formula 1 has high durability when stored or operated.

Abstract: The present invention relates to novel 5-pyrrolidinylsulfonyl isatin derivatives, non-peptidyl Caspase binding Radioligands (CbRs) and CbR-transporter conjugates derived from said isatin derivatives, diagnostic compositions comprising said compounds of the invention and their use for non-invasive diagnostic imaging.

Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R2?, R2?, R3, R4, R5, R6, R7 and R8 have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.

Abstract: The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

Abstract: A heterocyclic compound represented by Formula 1 below, an organic light-emitting diode including the same, and a flat panel display device including the organic light-emitting diode: where X is *—Ar1 or wherein Ar1, Ar2, R1, R2, R3, R4, Y1, Y2, Y3, Y4, a, b, c, and d are as defined in the specification.

Abstract: A heterocyclic compound represented by a general Formula 1 and an organic light-emitting device including the heterocyclic compound. In some embodiments the heterocyclic compound of Formula 1 may be used as a light-emitting material, a hole transporting material, or an electron transporting material. The heterocyclic compound of Formula 1 having a heterocyclic group in the molecules thereof has a high glass transition temperature (Tg) or a high melting point due to the inclusion of the heterocyclic group. Thus, the heterocyclic compound has high heat resistance against Joule's heat generated in an organic layer, between organic layers, or between an organic layer and a metal electrode when light emission occurs, and has high durability in high-temperature environments. An organic light-emitting device manufactured using the heterocyclic compound of Formula 1 has high durability when stored or operated.

Abstract: The present invention relates to a material for an organic electroluminescent device, including a phenanthrocarbazole-based compound having a specific structure, and an organic electroluminescent device including the same. More specifically, the phenanthrocarbazole-based compound is applied as a material for a phosphorescent and fluorescent organic electroluminescent device, thereby providing an organic light emitting device with improved light emitting efficiency, luminance, thermal stability, driving voltage, lifetime and the like.

Abstract: The present invention relates to novel ?4?2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them. The present invention relates to novel ?4?2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them.

Abstract: A preparation method of original dye of Vat Brown R comprises the following steps: a. after acylation of 1,5-diaminoanthraquinone, 1-amino-5-benzamidoanthraquinone was prepared by acidic hydrolysis; b. 1-benzamido-4-bromoanthraquinone was obtained from 1-aminoanthraquinone by acylation and bromination; c. a condensate of Vat Brown R was obtained by condensation reaction of 1-amino-5-benzamidoanthraquinone and 1-benzamido-4-bromoanthraquinone; d. the original dye of Vat Brown R was obtained from the condensate of Vat Brown R by ring closing reaction and oxidation reaction. The method omits one oxidation step, economizes significant amount of oxidizing agent, and reduces significant amount of waste water, so it is very beneficial to environment protection; and the method also exhibited the advantages of highly increasing product yield and reducing the costs of raw materials to an extent of more than 30%.

Abstract: A compound for an organic thin film transistor represented by the following formula (1):

Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

Abstract: The present invention makes reference to new indene derivatives with general formula (I), as well as to their preparation procedures, their application as medicament and the pharmaceutical compositions containing them. The new compounds of formula (I) show affinity for 5-HT6 receptors and are, therefore, effective for treating diseases mediated by these receptors.

Abstract: A substituted indolocarbazole comprising at least one optionally substituted thienyl.

Abstract: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

Abstract: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein R1 to R12 are defined as in the specification.

Abstract: The present invention describes indenocarbazole derivatives having electron- and hole-transporting properties, in particular for use in the emission and/or charge-transport layer of electroluminescent devices or as matrix material. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising same.

Abstract: An improved method for preparing ramipril is disclosed, and also an intermediate for use in the method.

Abstract: A substituted indolocarbazole comprising at least one optionally substituted thienyl.